Does the media favor NDRA or CTSO?

In the previous week, ENDRA Life Sciences had 1 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for ENDRA Life Sciences and 2 mentions for Cytosorbents. ENDRA Life Sciences' average media sentiment score of 0.96 beat Cytosorbents' score of 0.94 indicating that ENDRA Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ENDRA Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NDRA or POAI?

ENDRA Life Sciences currently has a consensus price target of $25.00, suggesting a potential upside of 414.40%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe ENDRA Life Sciences is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor LFWD or NDRA?

In the previous week, ENDRA Life Sciences had 1 more articles in the media than Lifeward. MarketBeat recorded 3 mentions for ENDRA Life Sciences and 2 mentions for Lifeward. ENDRA Life Sciences' average media sentiment score of 0.96 beat Lifeward's score of 0.94 indicating that ENDRA Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifeward 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ENDRA Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MODD or NDRA?

ENDRA Life Sciences has a consensus target price of $25.00, indicating a potential upside of 414.40%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Modular Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Modular Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, MODD or NDRA?

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Modular Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Modular Medical N/A N/A -$28.24M -$14.71 N/A ENDRA Life Sciences N/A N/A -$7.03M -$8.15 N/A

Is MODD or NDRA more profitable?

Modular Medical's return on equity of -286.34% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Modular Medical N/A -286.34% -216.26% ENDRA Life Sciences N/A -433.64% -204.58%

Does the media prefer MODD or NDRA?

In the previous week, Modular Medical and Modular Medical both had 3 articles in the media. ENDRA Life Sciences' average media sentiment score of 0.96 beat Modular Medical's score of 0.71 indicating that ENDRA Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Modular Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ENDRA Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ENDRA Life Sciences (NDRA) Competitors

$4.86 -0.37 (-7.07%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$5.02 +0.16 (+3.29%)

As of 07/24/2026 07:34 PM Eastern

Compare

NDRA vs. CTSO, POAI, NMTC, LFWD, and MODD

Should you buy ENDRA Life Sciences stock or one of its competitors? MarketBeat compares ENDRA Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ENDRA Life Sciences include Cytosorbents (CTSO), Predictive Oncology (POAI), NeuroOne Medical Technologies (NMTC), Lifeward (LFWD), and Modular Medical (MODD). These companies are all part of the "medical equipment" industry.

How does ENDRA Life Sciences compare to Cytosorbents?

ENDRA Life Sciences (NASDAQ:NDRA) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

ENDRA Life Sciences has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

ENDRA Life Sciences has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-433.64%	-204.58%
Cytosorbents	-31.85%	-235.57%	-37.88%

In the previous week, ENDRA Life Sciences had 1 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for ENDRA Life Sciences and 2 mentions for Cytosorbents. ENDRA Life Sciences' average media sentiment score of 0.96 beat Cytosorbents' score of 0.94 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ENDRA Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ENDRA Life Sciences has higher earnings, but lower revenue than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A
Cytosorbents	$37.06M	0.61	-$8.20M	-$0.19	N/A

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 7.8% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ENDRA Life Sciences presently has a consensus price target of $25.00, indicating a potential upside of 414.40%. Cytosorbents has a consensus price target of $5.38, indicating a potential upside of 1,393.06%. Given Cytosorbents' higher possible upside, analysts clearly believe Cytosorbents is more favorable than ENDRA Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cytosorbents beats ENDRA Life Sciences on 7 of the 13 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Predictive Oncology?

ENDRA Life Sciences (NASDAQ:NDRA) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

ENDRA Life Sciences has higher earnings, but lower revenue than Predictive Oncology. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A
Predictive Oncology	$1.66M	13.97	-$12.66M	-$13.50	N/A

In the previous week, ENDRA Life Sciences had 3 more articles in the media than Predictive Oncology. MarketBeat recorded 3 mentions for ENDRA Life Sciences and 0 mentions for Predictive Oncology. ENDRA Life Sciences' average media sentiment score of 0.96 beat Predictive Oncology's score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
ENDRA Life Sciences	Positive
Predictive Oncology	Neutral

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ENDRA Life Sciences has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

ENDRA Life Sciences has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. ENDRA Life Sciences' return on equity of -433.64% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-433.64%	-204.58%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

ENDRA Life Sciences currently has a consensus price target of $25.00, suggesting a potential upside of 414.40%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe ENDRA Life Sciences is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

ENDRA Life Sciences beats Predictive Oncology on 11 of the 15 factors compared between the two stocks.

How does ENDRA Life Sciences compare to NeuroOne Medical Technologies?

ENDRA Life Sciences (NASDAQ:NDRA) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

ENDRA Life Sciences has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -68.35%. NeuroOne Medical Technologies' return on equity of -99.43% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-433.64%	-204.58%
NeuroOne Medical Technologies	-68.35%	-99.43%	-70.40%

NeuroOne Medical Technologies has higher revenue and earnings than ENDRA Life Sciences. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A
NeuroOne Medical Technologies	$12.10M	1.37	-$3.61M	-$0.85	N/A

ENDRA Life Sciences has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

In the previous week, ENDRA Life Sciences had 1 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 3 mentions for ENDRA Life Sciences and 2 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 1.44 beat ENDRA Life Sciences' score of 0.96 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
ENDRA Life Sciences	Positive
NeuroOne Medical Technologies	Positive

ENDRA Life Sciences currently has a consensus price target of $25.00, suggesting a potential upside of 414.40%. NeuroOne Medical Technologies has a consensus price target of $11.67, suggesting a potential upside of 514.04%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than ENDRA Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

NeuroOne Medical Technologies beats ENDRA Life Sciences on 12 of the 15 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Lifeward?

Lifeward (NASDAQ:LFWD) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

26.8% of Lifeward shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 1.5% of Lifeward shares are owned by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ENDRA Life Sciences has a net margin of 0.00% compared to Lifeward's net margin of -123.66%. Lifeward's return on equity of -243.14% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifeward	-123.66%	-243.14%	-97.39%
ENDRA Life Sciences	N/A	-433.64%	-204.58%

In the previous week, ENDRA Life Sciences had 1 more articles in the media than Lifeward. MarketBeat recorded 3 mentions for ENDRA Life Sciences and 2 mentions for Lifeward. ENDRA Life Sciences' average media sentiment score of 0.96 beat Lifeward's score of 0.94 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifeward	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ENDRA Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ENDRA Life Sciences has lower revenue, but higher earnings than Lifeward. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03M	0.90	-$19.91M	-$19.66	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A

Lifeward has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Lifeward presently has a consensus price target of $10.00, suggesting a potential upside of 41.84%. ENDRA Life Sciences has a consensus price target of $25.00, suggesting a potential upside of 414.40%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe ENDRA Life Sciences is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

ENDRA Life Sciences beats Lifeward on 8 of the 14 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Modular Medical?

Modular Medical (NASDAQ:MODD) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

ENDRA Life Sciences has a consensus target price of $25.00, indicating a potential upside of 414.40%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Modular Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Modular Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

27.5% of Modular Medical shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 7.1% of Modular Medical shares are owned by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Modular Medical has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

In the previous week, Modular Medical and Modular Medical both had 3 articles in the media. ENDRA Life Sciences' average media sentiment score of 0.96 beat Modular Medical's score of 0.71 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Modular Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ENDRA Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Modular Medical's return on equity of -286.34% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Modular Medical	N/A	-286.34%	-216.26%
ENDRA Life Sciences	N/A	-433.64%	-204.58%

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Modular Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Modular Medical	N/A	N/A	-$28.24M	-$14.71	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A

Summary

ENDRA Life Sciences beats Modular Medical on 8 of the 12 factors compared between the two stocks.

Get ENDRA Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NDRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NDRA vs. The Competition

Export

Metric	ENDRA Life Sciences	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.17M	$7.45B	$6.93B	$12.20B
Dividend Yield	N/A	1.33%	2.67%	9.41%
P/E Ratio	-0.60	48.63	27.14	23.62
Price / Sales	N/A	85.01	523.81	89.60
Price / Cash	N/A	25.70	49.81	58.78
Price / Book	2.53	6.73	10.28	6.01
Net Income	-$7.03M	$162.27M	$3.60B	$331.99M
7 Day Performance	-2.61%	-5.05%	-1.27%	-0.63%
1 Month Performance	13.02%	-5.86%	-0.37%	-2.00%
1 Year Performance	-26.36%	-2.88%	18.30%	13.62%

ENDRA Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NDRA ENDRA Life Sciences	3.1676 of 5 stars	$4.86 -7.1%	$25.00 +414.4%	-26.0%	$6.17M	N/A	N/A	20	Short Interest Decrease Gap Up
CTSO Cytosorbents	2.4804 of 5 stars	$0.39 +2.2%	$5.38 +1,283.5%	-64.0%	$23.88M	$37.06M	N/A	220	Gap Up
POAI Predictive Oncology	N/A	$7.01 -4.8%	N/A	-38.7%	$23.79M	$1.66M	N/A	30
NMTC NeuroOne Medical Technologies	3.1565 of 5 stars	$2.43 -8.6%	$11.67 +380.1%	-64.9%	$23.15M	$12.10M	N/A	20	Positive News Short Interest Decrease
LFWD Lifeward	1.9245 of 5 stars	$8.00 +0.6%	$10.00 +25.0%	-28.9%	$22.38M	$22.03M	N/A	60	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NDRA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ENDRA Life Sciences (NDRA) Competitors

NDRA vs. CTSO, POAI, NMTC, LFWD, and MODD

How does ENDRA Life Sciences compare to Cytosorbents?

Summary

How does ENDRA Life Sciences compare to Predictive Oncology?

Summary

How does ENDRA Life Sciences compare to NeuroOne Medical Technologies?

Summary

How does ENDRA Life Sciences compare to Lifeward?

Summary

How does ENDRA Life Sciences compare to Modular Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NDRA vs. The Competition

ENDRA Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ENDRA Life Sciences (NDRA) Competitors

NDRA vs. CTSO, POAI, NMTC, LFWD, and MODD

How does ENDRA Life Sciences compare to Cytosorbents?

Which has more volatility and risk, NDRA or CTSO?

Is NDRA or CTSO more profitable?

Does the media favor NDRA or CTSO?

Which has stronger valuation and earnings, NDRA or CTSO?

Do institutionals & insiders have more ownership in NDRA or CTSO?

Do analysts rate NDRA or CTSO?

Summary

How does ENDRA Life Sciences compare to Predictive Oncology?

Which has better earnings and valuation, NDRA or POAI?

Does the media favor NDRA or POAI?

Do insiders & institutionals have more ownership in NDRA or POAI?

Which has more risk & volatility, NDRA or POAI?

Is NDRA or POAI more profitable?

Do analysts rate NDRA or POAI?

Summary

How does ENDRA Life Sciences compare to NeuroOne Medical Technologies?

Is NDRA or NMTC more profitable?

Which has preferable earnings and valuation, NDRA or NMTC?

Which has more risk & volatility, NDRA or NMTC?

Does the media prefer NDRA or NMTC?

Do analysts recommend NDRA or NMTC?

Do insiders & institutionals hold more shares of NDRA or NMTC?

Summary

How does ENDRA Life Sciences compare to Lifeward?

Do institutionals & insiders hold more shares of LFWD or NDRA?

Is LFWD or NDRA more profitable?

Does the media favor LFWD or NDRA?

Which has stronger earnings and valuation, LFWD or NDRA?

Which has more volatility and risk, LFWD or NDRA?

Do analysts recommend LFWD or NDRA?

Summary

How does ENDRA Life Sciences compare to Modular Medical?

Do analysts recommend MODD or NDRA?

Do insiders and institutionals believe in MODD or NDRA?

Which has more risk and volatility, MODD or NDRA?

Does the media prefer MODD or NDRA?

Is MODD or NDRA more profitable?

Which has better earnings & valuation, MODD or NDRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NDRA vs. The Competition

ENDRA Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools